N-Methyl-3,4-methylenedioxyamphetamine
Research News and Information

Monday, November 23, 2009

Sleep deprivation differentially impairs cognitive performance in abstinent methylenedioxymethamphetamine ("Ecstasy") users.

2 Nov 2009 Methylenedioxymethamphetamine (MDMA; "Ecstasy") is a popular recreational drug and brain serotonin (5-HT) neurotoxin. Neuroimaging data indicate that some human MDMA users develop persistent deficits in brain 5-HT neuronal markers. Although the ... Read more...

3,4-Methylenedioxymethamphetamine increases susceptibility to genital herpes simplex virus infection in mice.

13 Oct 2009 Abused by >1.2 million Americans, 3,4-methylenedioxymethamphetamine (MDMA) (commonly referred to as ecstasy) is popular in the dance club, rave, and circuit party scenes. MDMA and other similar drugs are reportedly associated with increased ... Read more...

MDMA pretreatment leads to mild chronic unpredictable stress-induced impairments in spatial learning.

29 Sep 2009 3,4-Methylenedioxymethamphetamine (MDMA) is a drug of abuse worldwide and a selective serotonin (5-HT) neurotoxin. An important factor in the risk of drug abuse and relapse is stress. Although multiple parallels exist between MDMA abuse and stress, ... Read more...

Latest indexed articles for 'N-Methyl-3,4-methylenedioxyamphetamine'

These are the very latest articles for this heading:

• Sleep deprivation differentially impairs cognitive performance in abstinent methylenedioxymethamphetamine ("Ecstasy") users. 2 Nov 2009
• 3,4-Methylenedioxymethamphetamine increases susceptibility to genital herpes simplex virus infection in mice. 13 Oct 2009
• MDMA pretreatment leads to mild chronic unpredictable stress-induced impairments in spatial learning. 29 Sep 2009
• Methylenedioxymethamphetamine-related deaths in Taiwan: 2001-2008. 30 Aug 2009
• Acute hippocampal sclerosis following ecstasy ingestion. 16 Aug 2009
• Drug-induced fibrotic valvular heart disease. 13 Aug 2009
• Learning and memory deficits in ecstasy users and their neural correlates during a face-learning task. 21 Jul 2009
• Methylenedioxymethamphetamine (MDMA)-related fatalities in Australia: demographics, circumstances, toxicology and major organ pathology. 12 Jul 2009
• A structured review of reasons for ecstasy use and related behaviours: pointers for future research. 11 Jul 2009
• Investigations on the human hepatic cytochrome P450 isozymes involved in the metabolism of 3,4-methylenedioxy-amphetamine (MDA) and benzodioxolyl-butanamine (BDB) enantiomers. 30 Jun 2009
• Modulation of MDMA-induced behavioral and transcriptional effects by the delta opioid antagonist naltrindole in mice. 29 Jun 2009
• Repeated exposure to MDMA provides neuroprotection against subsequent MDMA-induced serotonin depletion in brain. 21 Jun 2009
• Differential changes in mesolimbic dopamine following contingent and non-contingent MDMA self-administration in mice. 2 Jun 2009
• Hallucinogen-related disorders in a national sample of adolescents: the influence of ecstasy/MDMA use. 2 Jun 2009
• Direct comparison of (+/-) 3,4-methylenedioxymethamphetamine ("ecstasy") disposition and metabolism in squirrel monkeys and humans. 30 May 2009
• Unsuspected exposure to cocaine in preschool children from a Mediterranean city detected by hair analysis. 30 May 2009
• A comparison between experimental and authentic blood/serum ratios of 3,4-methylenedioxymethamphetamine and 3,4-methylenedioxyamphetamine. 30 May 2009
• Movement disorders and MDMA abuse. 30 May 2009
• Young adult Ecstasy users' enhancement of the effects of their Ecstasy use. 30 May 2009
• Enantioselectivity in the methylation of the catecholic phase I metabolites of methylenedioxy designer drugs and their capability to inhibit catechol-O-methyltransferase-catalyzed dopamine 3-methylation. 30 May 2009

See a longer list of these articles.

Technical information about 'N-Methyl-3,4-methylenedioxyamphetamine'

Definition: An N-substituted amphetamine analog. It is a widely abused drug classified as a hallucinogen and causes marked, long-lasting changes in brain serotonergic systems. It is commonly referred to as MDMA or ecstasy.

Chemical name: 1,3-Benzodioxole-5-ethanamine, N,alpha-dimethyl-

Registry Number: 42542-10-9

Descriptor UI: D018817

Alternative terms: N-Methyl-3,4-methylenedioxyamphetamine; N Methyl 3,4 methylenedioxyamphetamine; MDMA; Methylenedioxymethamphetamine; Ecstasy (Drug); N-Methyl-3,4-methylenedioxyamphetamine Hydrochloride; Hydrochloride, N-Methyl-3,4-methylenedioxyamphetamine; N Methyl 3,4 methylenedioxyamphetamine Hydrochloride;

Allowable Qualifiers: administration & dosage; adverse effects; analogs & derivatives; analysis; antagonists & inhibitors; blood; cerebrospinal fluid; chemical synthesis; classification; diagnostic use; economics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; poisoning; radiation effects; standards; supply & distribution; therapeutic use; toxicity; urine; chemistry; contraindications; agonists;

Pharmacological Action: Hallucinogens; Serotonin Agents; Adrenergic Uptake Inhibitors;

Tree Number: D02.092.471.683.152.670;

Online Note: use N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE (NM) to search N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE 1984-94

History Note: 95; was N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE (NM) 1984-94

Technical Notes: street drug Ecstasy goes here; DF: note short X ref